featured
No Overall Survival Benefit With Addition of Bevacizumab to Radiotherapy/Temozolomide in Glioblastoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine